PRINCETON, N.J., Nov. 18, 2019 /PRNewswire/
-- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the
Company), a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need, announced today that it
will be presenting at the PCG Spotlight Series Conference taking
place on Thursday, November 21, 2019
at the Harvard Club, 35 West 44th Street, NYC at 2:30 pm
EST. Christopher J. Schaber,
PhD, President and Chief Executive Officer of Soligenix will be
delivering the corporate presentation and reviewing upcoming
milestones for the Company's two pivotal Phase 3 clinical
programs.
Interested investors may contact ksmith@pcgadvisory.com to
attend and/or arrange for a one-on-one meeting.
About PCG Advisory, Inc.
PCG Advisory is a leading
investor relations firm dedicated to the delivery of top-tier
strategic services that encompass investor relations, capital
markets navigation, and corporate communications for innovative and
emerging companies from around the globe. PCG Advisory has
extensive experience with life science, fintech and blockchain
technology companies. For more information, go
to www.pcgadvisory.com
About Soligenix, Inc.
Soligenix is a late-stage
biopharmaceutical company focused on developing and commercializing
products to treat rare diseases where there is an unmet medical
need. Our Specialized BioTherapeutics business segment is
developing SGX301 as a novel photodynamic therapy utilizing safe
visible light for the treatment of cutaneous T-cell lymphoma, our
first-in-class innate defense regulator (IDR) technology,
dusquetide (SGX942) for the treatment of oral mucositis in head and
neck cancer, and proprietary formulations of oral beclomethasone
17,21-dipropionate (BDP) for the prevention/treatment of
gastrointestinal (GI) disorders characterized by severe
inflammation including pediatric Crohn's disease (SGX203) and acute
radiation enteritis (SGX201).
Our Public Health Solutions business segment includes active
development programs for RiVax®, our ricin toxin vaccine
candidate, OrbeShield®, our GI acute radiation syndrome
therapeutic candidate and SGX943, our therapeutic candidate for
antibiotic resistant and emerging infectious disease. The
development of our vaccine programs incorporates the use of our
proprietary heat stabilization platform technology, known as
ThermoVax®. To date, this business segment has been
supported with government grant and contract funding from the
National Institute of Allergy and Infectious Diseases (NIAID), the
Defense Threat Reduction Agents (DTRA) and the Biomedical Advanced
Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit
the Company's website at www.soligenix.com.
This press release may contain forward-looking statements that
reflect Soligenix, Inc.'s current expectations about its future
results, performance, prospects and opportunities, including but
not limited to, potential market sizes, patient populations and
clinical trial enrollment. Statements that are not historical
facts, such as "anticipates," "estimates," "believes," "hopes,"
"intends," "plans," "expects," "goal," "may," "suggest," "will,"
"potential," or similar expressions, are forward-looking
statements. These statements are subject to a number of risks,
uncertainties and other factors that could cause actual events or
results in future periods to differ materially from what is
expressed in, or implied by, these statements. Soligenix
cannot assure you that it will be able to successfully develop,
achieve regulatory approval for or commercialize products based on
its technologies, particularly in light of the significant
uncertainty inherent in developing therapeutics and vaccines
against bioterror threats, conducting preclinical and clinical
trials of therapeutics and vaccines, obtaining regulatory approvals
and manufacturing therapeutics and vaccines, that product
development and commercialization efforts will not be reduced or
discontinued due to difficulties or delays in clinical trials or
due to lack of progress or positive results from research and
development efforts, that it will be able to successfully obtain
any further funding to support product development and
commercialization efforts, including grants and awards, maintain
its existing grants which are subject to performance requirements,
enter into any biodefense procurement contracts with the U.S.
Government or other countries, that it will be able to compete with
larger and better financed competitors in the biotechnology
industry, that changes in health care practice, third party
reimbursement limitations and Federal and/or state health care
reform initiatives will not negatively affect its business, or that
the U.S. Congress may not pass any legislation that would provide
additional funding for the Project BioShield program. In addition,
there can be no assurance as to the timing or success of the Phase
3 clinical trial of SGX942 (dusquetide) as a treatment for oral
mucositis in patients with head and neck cancer receiving
chemoradiation therapy or the Phase 3 clinical trial of SGX301
(synthetic hypericin) for the treatment of cutaneous T-cell
lymphoma, or any of our other clinical/preclinical trials. Further,
there can be no assurance that RiVax® will qualify for a
biodefense Priority Review Voucher (PRV) or that the prior sales of
PRVs will be indicative of any potential sales price for a PRV for
RiVax®. Also, no assurance can be provided that the
Company will receive or continue to receive non-dilutive government
funding from grants and contracts that have been or may be awarded
or for which the Company will apply in the future. These and
other risk factors are described from time to time in filings with
the Securities and Exchange Commission, including, but not limited
to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by
law, Soligenix assumes no obligation to update or revise any
forward-looking statements as a result of new information or future
events.
View original
content:http://www.prnewswire.com/news-releases/soligenix-to-present-at-the-pcg-spotlight-series-conference-300959459.html
SOURCE Soligenix, Inc.